Treace Medical Concepts, Inc. - Common Stock (TMCI)
6.3900
+0.2600 (4.24%)
NASDAQ · Last Trade: Aug 11th, 7:33 PM EDT
Detailed Quote
Previous Close
6.130
Open
6.180
Bid
6.390
Ask
7.130
Day's Range
5.845 - 6.460
52 Week Range
4.540 - 10.79
Volume
515,225
Market Cap
391.91M
PE Ratio (TTM)
-8.089
EPS (TTM)
-0.8
Dividend & Yield
N/A (N/A)
1 Month Average Volume
306,702
Chart
About Treace Medical Concepts, Inc. - Common Stock (TMCI)
Treace Medical Concepts Inc is a medical technology company focused on developing and commercializing innovative solutions for foot and ankle surgery. The company specializes in advanced surgical techniques and devices aimed at improving patient outcomes, particularly in conditions such as bunions and other foot deformities. Treace Medical provides surgeons with minimally invasive products that enhance the precision and efficiency of surgical procedures, ultimately helping patients achieve quicker recovery times and improved mobility. Through ongoing research and development, Treace Medical strives to remain at the forefront of the orthopedic medical device industry. Read More
PONTE VEDRA, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced plans to host an investor day at 9:00 am E.T. on September 3, 2025, in New York, New York. The event will include presentations by members of management and experienced surgeon users, highlighting their experiences with the expanded technology portfolio.
PONTE VEDRA, Fla., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced the peer-reviewed publication of the four-year interim results from its ALIGN3D™ multicenter prospective study demonstrating positive clinical and radiographic outcomes of the Lapiplasty® Procedure in the Journal of Foot & Ankle Surgery.
PONTE VEDRA, Fla., July 24, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that it will release financial results for the second quarter 2025 after the close of trading on Thursday, August 7, 2025. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET.
